North America Revenue
$250M
+13% YoY
All-time high quarterly revenue driven by Lanreotide generic launch and Albuterol market share gains.
CIPLA
Healthcare
26 Jul 2024
Cipla Ltd — Q1 FY25
Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing. North America hit an all-time high of $250 million (+13% YoY), supported by Lanreotide generic launch and Albuterol market share gains to 17%. India branded prescription grew 10% YoY, while trade generic transition was completed, impacting near-term growth. PAT stood at INR 1,178 crore (17.6% of sales). Management guided EBITDA margin of 24.5%-25.5% for FY25 and expects U.S. sustainable run rate of $235-240 million. Key risks include Goa facility FDA classification (six 483 observations) and potential price erosion in Albuterol with new entrants.
सिप्ला ने पहली तिमाही (अप्रैल-जून 2024) में अच्छा प्रदर्शन किया। कंपनी की कमाई 6,694 करोड़ रुपये रही, जो पिछले साल से 7% ज्यादा है। मुनाफा (EBITDA) 25.6% रहा, जो पिछले साल से 1.54% बेहतर है। इसकी वजह अच्छा उत्पाद मिश्रण और सही कीमतें थीं। अमेरिका में बिक्री 250 मिलियन डॉलर (सबसे ज्यादा) पहुंची, जो 13% बढ़ी। भारत में ब्रांडेड दवाओं की बिक्री 10% बढ़ी। कंपनी का शुद्ध मुनाफा 1,178 करोड़ रुपये रहा। आगे साल भर में मुनाफा 24.5% से 25.5% रहने का अनुमान है। अमेरिका में हर तिमाही 235-240 मिलियन डॉलर की बिक्री होने की उम्मीद है। जोखिम: गोवा फैक्ट्री पर FDA की नजर है और एल्ब्युटेरोल दवा की कीमत गिर सकती है।
Key Numbers
Albuterol Market Share
17%
+4pp QoQ
Recaptured market share in Albuterol, gaining 4% in the quarter.
India Chronic Mix
61.5%
+106bps YoY
Chronic share improved to 61.5% as per IQVIA MAT June 2024, indicating better therapy mix.
Lanreotide Market Share
20%
flat
Maintained 20% market share for Lanreotide 505(b)(2) during the quarter.
What Changed vs Last Quarter
NEW
U.S. sustainable quarterly run rate of $235-240 million
Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.
NEW
Two peptide launches expected in H2 FY25
Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.
NEW
Advair filing by end of 2024, potential launch in H1 CY2025
ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
UPDATED
EBITDA margin guidance of 24.5%-25.5% for FY25
Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.
DROPPED
Capex of INR 1,500 crore in FY25
Capital investments planned to enhance manufacturing capability and sustainability.
DROPPED
North America revenue growth aspiration for FY25
Aim to grow top line YoY, backed by commercial execution of existing portfolio and new launches.
DROPPED
Launch of 4 peptide assets in FY25
Targeting to launch four peptide assets during the fiscal year.
NEW RISK
Goa facility FDA classification pending
Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
NEW RISK
Potential price erosion from new Albuterol entrants
New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
NEW RISK
Lanreotide supply constraints limiting ramp-up
Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
NEW RISK
Trade generic transition disruption
Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains.
RISK GONE
USFDA observations at Patalganga and Kurkumbh facilities
Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
RISK GONE
Trade generics channel restructuring disruption
Transition to direct stockist model may cause temporary hiccups in Q1 FY25, impacting trade generics growth.
RISK GONE
Timing uncertainty for Goa plant reinspection and Abraxane launch
Goa plant reinspection expected around July-August 2024; Abraxane launch depends on inspection outcome and subsequent 90-day process.
RISK GONE
Potential pricing pressure in Lanreotide market
As a two-player market, pricing may vary depending on competitor actions, though management aims to grow total value.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
Mentioned in Q1 FY24, Q2 FY24
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Mentioned in Q1 FY24, Q3 FY24
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
Mentioned in Q1 FY24, Q4 FY24
As a two-player market, pricing may vary depending on competitor actions, though management aims to grow total value.
Mentioned in Q3 FY24, Q4 FY24
Goa plant reinspection expected around July-August 2024; Abraxane launch depends on inspection outcome and subsequent 90-day process.
Management Guidance
EBITDA margin guidance of 24.5%-25.5% for FY25
Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.
Management guidance marginsU.S. sustainable quarterly run rate of $235-240 million
Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.
Management guidance revenueTwo peptide launches expected in H2 FY25
Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.
Management guidance growthAdvair filing by end of 2024, potential launch in H1 CY2025
ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
Management guidance growthKey Risks
Goa facility FDA classification pending
Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
high · management_commentaryPotential price erosion from new Albuterol entrants
New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
medium · analyst_questionLanreotide supply constraints limiting ramp-up
Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
medium · analyst_questionTrade generic transition disruption
Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains.
low · management_commentaryNotable Quotes
North America reached all-time high quarterly revenue of $250 million.
Our EBITDA for the year is trending in the range of 24.5%-25.5% and ROIC is well over 30%.
The ANDA launch should hopefully add to this overall share. I think the ANDA also looks like any other product has a time to ramp up.
Frequently Asked Questions
What was Cipla's revenue in Q1 FY25?
Cipla reported revenue of ₹6,694 Cr in Q1 FY25, representing a +7% change compared to the same quarter last year.
What guidance did Cipla management give for FY26?
EBITDA margin guidance of 24.5%-25.5% for FY25: Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance. U.S. sustainable quarterly run rate of $235-240 million: Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits. Two peptide launches expected in H2 FY25: Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years. Advair filing by end of 2024, potential launch in H1 CY2025: ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
What are the key risks for Cipla in FY26?
Key risks include Goa facility FDA classification pending — Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.; Potential price erosion from new Albuterol entrants — New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.; Lanreotide supply constraints limiting ramp-up — Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.; Trade generic transition disruption — Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains..
Did Cipla meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Cipla Q1 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.